Sinphar Financial Statements From 2010 to 2024
| 1734 Stock | TWD 31.15 0.05 0.16% |
Check Sinphar Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sinphar Pharmaceutical's main balance sheet or income statement drivers, such as , as well as many indicators such as . Sinphar financial statements analysis is a perfect complement when working with Sinphar Pharmaceutical Valuation or Volatility modules.
Sinphar |
Sinphar Pharmaceutical Co Company Current Valuation Analysis
Sinphar Pharmaceutical's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Sinphar Pharmaceutical Current Valuation | 6.26 B |
Most of Sinphar Pharmaceutical's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sinphar Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Sinphar Pharmaceutical Co has a Current Valuation of 6.26 B. This is 56.45% lower than that of the Pharmaceuticals sector and 34.66% higher than that of the Health Care industry. The current valuation for all Taiwan stocks is 62.37% higher than that of the company.
Sinphar Pharmaceutical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sinphar Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Sinphar Pharmaceutical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sinphar Pharmaceutical competition to find correlations between indicators driving Sinphar Pharmaceutical's intrinsic value. More Info.Sinphar Pharmaceutical Co is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers reporting about 0.47 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Sinphar Pharmaceutical Co is roughly 2.14 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sinphar Pharmaceutical's earnings, one of the primary drivers of an investment's value.About Sinphar Pharmaceutical Financial Statements
Sinphar Pharmaceutical investors use historical fundamental indicators, such as Sinphar Pharmaceutical's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Sinphar Pharmaceutical. Please read more on our technical analysis and fundamental analysis pages.
,Ltd., together with its subsidiaries, researches, develops, manufactures, and sells therapeutic drugs, health care foods, and medical beauty products in Taiwan and internationally. ,Ltd. was founded in 1977 and is headquartered in Yilan, Taiwan. SINPHAR PHARMACEUTICAL operates under Biotechnology classification in Taiwan and is traded on Taiwan Stock Exchange.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Sinphar Stock Analysis
When running Sinphar Pharmaceutical's price analysis, check to measure Sinphar Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sinphar Pharmaceutical is operating at the current time. Most of Sinphar Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Sinphar Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sinphar Pharmaceutical's price. Additionally, you may evaluate how the addition of Sinphar Pharmaceutical to your portfolios can decrease your overall portfolio volatility.